Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok2. fázis

Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis

A legfontosabb adatok

Ki végzi
The Cleveland Clinic
Hol
Cleveland (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
15 fő, tervezett
Kezdés
2025. jún. 1.
Várható befejezés
2030. dec.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Ruxolitinib Topical Cream
A regiszteradat frissítve
2026. október 28.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with dermatomyositis whose skin symptoms continue despite earlier treatment. It tests ruxolitinib 1.5% cream applied to the skin.

Életkor
18 Years to 89 Years
Nem
All sexes can join.
A betegség stádiuma
Classic, juvenile or amyopathic dermatomyositis with active skin disease that has not responded to treatment. A skin biopsy must show dermatomyositis. Affected skin must be BSA>1% to <20%, CDASI activity score > 6, and PGA activity score >2.
Korábbi kezelés
People must have had systemic corticosteroids and at least one other steroid-sparing systemic treatment, for example methotrexate or mycophenolate mofetil. They must have tried at least one skin medicine that did not work, with the last use more than 2 weeks before joining. Their systemic medicines must have been stable for at least 2 months (60 days) and must stay stable during the trial.

A részvétel fő kizáró okai

  • Little or no active skin disease, or more than 20% of the body skin affected.
  • Used a prescription skin medicine in the previous 2 weeks.
  • Currently taking a Janus kinase inhibitor pill, or poor response to one before, or poor response to a Janus kinase inhibitor cream.
  • Other types of muscle inflammation, such as polymyositis, inclusion body myositis, or overlap myositis.
  • Active cancer other than non-melanoma skin cancer, or dermatomyositis linked to cancer.

A regiszter feltételei, szó szerint

Mind a 17 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients 18 years and older with refractory cutaneous symptoms related to either classic dermatomyositis (CD), juvenile dermatomyositis (JD), or amyopathic dermatomyositis (AD). Diagnosis will be based on either Bohan and Peter criteria (CD and JD) or Sontheimer's criteria (AD) (19-22)
  • Patients must have had a skin biopsy with histologic features consistent with dermatomyositis and current cutaneous manifestations consistent with dermatomyositis
  • Patients will be considered to have refractory disease if cutaneous manifestations exist despite treatment with systemic corticosteroids and at least one steroid-sparing systemic treatment commonly found to be useful in patients with dermatomyositis. These may include azathioprine, cyclosporine, mycophenolate mofetil, IVIG, methotrexate, hydroxychloroquine, cyclophosphamide, chlorambucil, sirolimus, tacrolimus, and rituximab
  • Patients must have sufficiently active cutaneous involvement of dermatomyositis (BSA>1% to <20%, CDASI activity score > 6, and Physician Global Assessment (PGA) activity score >2)
  • Patients must have tried and failed at least one commonly prescribed topical medication in the past, with the last application of a topical medication to active skin lesions occurring greater than 2 weeks prior to enrollment; o Commonly prescribed topical medications for dermatomyositis include corticosteroids or calcineurin inhibitors (tacrolimus or pimecrolimus)
  • Patients must have been on a stable systemic medication regimen for at least 2 months (60 days) and must agree to keep the regimen stable throughout the study period. As patients with dermatomyositis are commonly treated with combination regimens that include both topical and systemic immunosuppressive medications, any added risk of adverse effects related to ruxolitinib 1.5% cream is considered negligible
  • Patients must be agreeable to use appropriate contraceptive measures while enrolled in the study; Women of childbearing potential must be willing to practice abstinence or use either an oral contraceptive medication or IUD if sexually active; Women of childbearing potential must be willing to have monthly urine pregnancy tests while enrolled in the study; Men of childbearing potential must be willing to practice abstinence or use condoms if sexually active

Ki nem vehet részt

  • Patients who have used a common prescription topical medication within the previous 2 weeks
  • Patients whose cutaneous findings are not consistent with dermatomyositis and/or have previous biopsy results suggestive of an alternative diagnosis
  • Patients not on stable systemic medication regimens for at least 2 months and/or who will not agree to keep the regimen stable throughout the study period
  • Patients who have previously taken a systemic Janus kinase inhibitor but had a poor response, patients who are currently taking systemic Janus kinase inhibitors, or patients who have used a topical Janus kinase inhibitor for their dermatomyositis or any other condition and had poor responses
  • Patients with dermatomyositis who have minimal-to-no active cutaneous disease (mild involvement with < 1% total body surface area involved and/or CDASI activity score of < 6)
  • Patients with clear features of an overlap autoimmune myositis or with an inflammatory myositis not consistent with dermatomyositis, such as polymyositis or inclusion body myositis
  • Patients with an active malignancy other than non-melanoma skin cancer, or with malignancy-associated dermatomyositis
  • Patients younger than 18 years old
  • Patients who have > 20% total BSA involvement of cutaneous dermatomyositis
  • Patients with inflammatory myositis other than dermatomyositis, such as polymyositis or inclusion body myositis

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 89 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • Cleveland ClinicCleveland, Egyesült ÁllamokContact: Anthony Fernandez, MDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study will assess the safety and efficacy of topical ruxolitinib for treating the refractory cutaneous manifestations in patients with dermatomyositis. The investigators' hypothesis is that topical ruxolitinib will be both safe and effective for such patients.

A vizsgálat csoportja

  • TreatmentA vizsgált kezelés

    1.5 % Ruxolitinib cream

    Kezelés: Ruxolitinib Topical Cream

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT06857240: ki vehet részt
A regiszteradat frissítve
2026. október 28.